Currently, patients with metastatic HR-/HER2+ advanced breast cancer are primarily treated with a combination of chemotherapy and targeted antibodies, but these treatments often come with significant side effects.
BAMF Health’s new study addresses the concept that if an imaging agent can identify whether lesions are expressing a certain target, that same target could be used to deliver radiopharmaceutical treatment in the future. Director of Clinical Trials Dan Rogers explains:
“Using that target, we can image the patient and see where does that disease sit, how much disease does that patient have, what therapy would be appropriate for that patient.”
BAMF specializes in theranostics, which combines molecular imaging with radiopharmaceutical imaging therapy. It’s proven successful in treating prostate cancer, and now BAMF wants to bring the same benefits to breast cancer patients. Chief Medical Advisor Dr. Harshad Kulkarni explains.
“It’s not a novel agent that we are testing. It’s a routine imaging, but it will give us a wealth of information.”
To see if you qualify for the study, you can check the clinical trials section of BAMF Health’s website.
